Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Center for Drug Evaluation and Research says its discussions with Genentech about a proposed confirmatory trial in metastatic breast cancer are irrelevant to the withdrawal of bevacizumab's accelerated approval for the indication.

You may also be interested in...



Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing

FDA hearing officer Karen Midthun rejects the Center for Drug Evaluation and Research's request to bar evidence on discussions over a new study of Avastin in first-line metastatic breast cancer.

Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing

FDA hearing officer Karen Midthun rejects the Center for Drug Evaluation and Research's request to bar evidence on discussions over a new study of Avastin in first-line metastatic breast cancer.

Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim

Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.

Related Content

Topics

UsernamePublicRestriction

Register

PS072253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel